J&J: encouraging results in hypertension
(CercleFinance.com) - Johnson & Johnson's Janssen Pharmaceutical Companies yesterday announced the results of a Phase III study showing that the investigational therapy combining macitentan 10 mg and tadalafil 40 mg in a single tablet led to a "significant" improvement in pulmonary hemodynamics (i.
e. blood flow in the pulmonary blood vessels) compared to monotherapies with macitentan. (i.e. blood flow in the pulmonary blood vessels) compared to monotherapy with macitentan and tadalafil in patients with World Health Organisation (WHO) functional class II or III pulmonary arterial hypertension (PAH).
J&J said PAH is a rare, progressive and potentially fatal disease of the blood vessels. It is characterised by constriction of the small pulmonary arteries and an increase in blood pressure that eventually leads to heart failure.
The results of the study were presented at the 72nd Annual Scientific Session and Exhibition of the American College of Cardiology at the World Heart Federation's World Congress of Cardiology.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
e. blood flow in the pulmonary blood vessels) compared to monotherapies with macitentan. (i.e. blood flow in the pulmonary blood vessels) compared to monotherapy with macitentan and tadalafil in patients with World Health Organisation (WHO) functional class II or III pulmonary arterial hypertension (PAH).
J&J said PAH is a rare, progressive and potentially fatal disease of the blood vessels. It is characterised by constriction of the small pulmonary arteries and an increase in blood pressure that eventually leads to heart failure.
The results of the study were presented at the 72nd Annual Scientific Session and Exhibition of the American College of Cardiology at the World Heart Federation's World Congress of Cardiology.
Copyright (c) 2023 CercleFinance.com. All rights reserved.